Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients by Dooley, M J et al.
Rounding of low serum creatinine levels and consequent impact
on accuracy of bedside estimates of renal function in cancer
patients
MJ Dooley*,1,2,4, S Singh
1 and D Rischin
3
1Pharmacy Department, Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne 3002, Australia;
2Department of Pharmacy Practice,
Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville 3052, Australia;
3Department of Haematology and Medical Oncology,
Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne 3002, Australia
To compare glomerular filtration rate measured by technetium-99m ([Tc
99m]) DTPA clearance with estimated creatinine clearance
(CrCl) (Cockcroft and Gault (C&G) method) in patients with serum creatinine (Scr) levels o0.06mmoll
 1, and determine the effect
of rounding serum creatinine to 0.06mmoll
 1. Patients with serum creatinine values o0.06mmoll
 1 at the time of [Tc
99m]
clearance determination were identified. Creatinine clearance was calculated by the C&G method using both actual and rounded Scr
values. A total of 419 adults had GFR measured by technetium-99m diethyl triamine penta-acetic acid ([Tc
99m] DTPA) clearance.
Out of this group, 26 patients had a serum creatinine value o0.06mmoll
 1. The C&G estimates of renal function using actual serum
creatinine resulted in an overall overestimation of 12.9% when compared to [Tc
99m] DTPA clearance. When the value of serum
creatinine was rounded to 0.06mmoll
 1, the formula underestimated renal function by  7.0%. Analysis of estimated creatinine
clearance for different levels of renal function showed significant differences to [Tc
99m] DTPA clearance. Rounding up of serum
creatinine to 0.06mmoll
 1 improved the predictive ability of the C&G method for the patients with [Tc
99m] DTPA clearance
p100mlmin
 1, but worsened the effect in those 4100mlmin
 1. This work indicates that when bedside estimates of renal function
are calculated using the C&G formula actual Scr should be used first to estimate CrCl. If the resultant CrCl is p100mlmin
 1, then
the Scr should be rounded up to 0.06mmoll
 1 and CrCl recalculated. Further assessment of this approach is warranted in a larger
cohort of patients.
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An assessment of renal function is required when determining the
dosage of cytotoxic drugs that are renally excreted. Ideally, a
method for estimating glomerular filtration rate (GFR) is required
that may be performed at the bedside. Any such estimate needs to
be accurate, convenient and inexpensive, and consequently should
be a noninvasive formula-based method, which does not require
multiple blood samples or tedious urine collection. Creatinine
clearance (CrCl) measurement, through 24-h urine collection, has
been used to estimate renal function; however, the reliability of this
method is very much dependent on an accurate and complete
urine collection, and is therefore frequently unsuitable (Davila and
Gardner 1987; McDermott et al, 1987; Chambers et al, 1990; Luke
et al, 1990; Robinson et al, 1990; Tsubaki et al, 1993; Millward et al,
1996). Various equations and nomograms have been developed to
estimate CrCl from serum creatinine (Scr) concentration (Jelliffe,
1973; Cockcroft and Gault 1976; Martin et al, 1998; Wright et al,
2001).
In practice, some patients are encountered who have very low
Scr. When such low results are incorporated into various formulae
to estimate CrCl, there is concern that this may result in an
inaccurate prediction. It has been a common clinical practice to
round up the Scr level of these patients when using bedside
estimates of renal function (Bertino, 1993; Smythe et al, 1994). In
addition, various clinical trials have stipulated this requirement,
for example, the current Phase III GOG clinical trial in first-line
treatment of ovarian cancer (GOG182). The most common
scenario is to arbitrarily round Scr levels o0.06 to 0.06mmoll
 1
and incorporate this into the Cockcroft and Gault (C&G) formula
to estimated renal function. It is recognised by clinicians that this
is a subjective decision. One of the reasons for the practice of
‘rounding up’ is concern with respect to the potential over-
estimation of renal function if very low Scr is used. Using an
overestimate of renal function could result in the potential of
overdosing of patients with cytotoxic chemotherapy agents, such
as carboplatin, especially in patients with low Scr postoperatively
who may be malnourished.
The validity of this ‘rounding up’ approach has not been
determined. An accurate measurement of GFR is possible by
measuring the clearance of the radiolabelled isotopes such as
technetium-99m diethyl triamine penta-acetic acid ([Tc
99m]
DTPA) and chromium 51-ethylene diamine tetra-acetic acid
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51 EDTA) (Rehling et al, 1984; Fawdry et al, 1985; Peters, 1991;
Millward et al, 1996). The aim of this study was to compare
measured GFR [Tc
99m] DTPA with estimated CrCl –calculated by
the C&G method in patients with Scr levels o0.06mmoll
 1, and
determine implication of rounding Scr to 0.06mmoll
 1.
MATERIALS AND METHODS
This was a retrospective study of adult patients with cancer who
had GFR measured by [Tc
99m] DTPA clearance at the Peter
MacCallum Cancer Centre between March 2000 and June 2003.
Patients with Scr values o0.06mmoll
 1 at the time of [Tc
99m]
DTPA clearance determination were identified. Height and actual
body weight were measured. Age and gender were recorded.
GFR was determined by [Tc
99m] DTPA clearance (Dooley et al,
2002). [Tc
99m] DTPA was prepared 30–60min prior to injection
using fresh elute and a current DTPA kit (Amersham International
formulation). Instant thin layer chromatography was performed
on all DTPA preparations approximately 30min after reconstitu-
tion of the kit and at the time of dose administration. Radioactivity
was sampled in a Well scintillation counter to confirm labelling
efficiency of greater than 98%. [Tc
99m] DTPA (400MBq) was
administered via a three-way tap and cannula to enable correlation
with renal imaging. A 10ml sodium chloride 0.9% flush per dose
ensured no dose residue in any of the apparatus. Dose apparatus
and injection site were checked for dose residue using a
scintillation probe. Blood samples (10ml) were taken at baseline
and at 2, 3 and 4h postinjection. Plasma was separated and counts
obtained. The clearance of [Tc
99m] DTPA was calculated from a
single exponential derived from the blood samples between 2 and
4h after injection. The GFR was calculated without correction for
body surface area (BSA).
Scr was measured using an alkaline picrate kinetic method, with
Roche Diagnostic Hitachi 912 reagent. Creatinine clearance was
then calculated by the C&G method using Eq. (1) from both actual
Scr value and then rounded to 0.06mmoll
 1. Body surface area
(Mosteller, 1987) and body mass index (BMI) (World Health
Organization, 2000) were calculated using Eqs. (2) and (3).
creatinineclearanceðmlmin 1Þ
¼½ ð 140   ageÞ actualbodyweight  
½1  ð sex 0:15Þ =ð0:814 ScrÞðCockcroft and Gault;1976Þ
ð1Þ
where the actual body weight is measured in kilograms, Scr is
measured in micromoles per litre, age in years and sex¼0\ (males)
or 1\ (females).
BSAðm2Þ¼ð height weight=3600Þ
1=2ðMosteller;1987Þð 2Þ
where BSA is measured in square metres, height in centimeters and
body weight in kilograms
BMIðkgm
 2Þ¼weight=height
2
ðWorldHealthOrganisation;2000Þ
ð3Þ
where weight is measured in kilograms and height in metres.
The difference between the measured GFR and estimated CrCl
were examined to determine whether prediction error was
independent of measurement magnitude. Analyses of differences
were used to determine bias and precision. Bias was assessed by
mean percentage error (MPE), calculated as the percentage
difference between the estimated CrCl and measured GFR. A
positive bias indicates overestimation of GFR and a negative bias
indicates underestimation. Paired t-test was used to compare the
actual and corrected CrCl at a¼0.05 with [Tc
99m] DTPA measured
GFR.
RESULTS
A total of 419 adults had GFR measured by [Tc
99m] DTPA
clearance during the period under study (March 2000 and June
2003). In all, 26 adult patients in this group were found to have Scr
value of o0.06mmoll
 1. There were 11 males and 15 females.
Patient demographics are detailed in Table 1.
Results of measured GFR and estimated CrCl are detailed in
Table 2 and shown graphically in Figures 1–4. There were 25
patients with Scr of 0.05mmoll
 1 and one patient with Scr of
0.04mmoll
 1.
The C&G estimates of renal function using actual Scr resulted in
an overall overestimation of 12.9% when compared to [Tc
99m]
DTPA clearance. When the value of Scr was rounded to
0.06mmoll
 1, the formula underestimated renal function by
 7.0%.
The analysis of estimated CrCl for different levels of renal
function showed significant differences to [Tc
99m] DTPA clearance.
Patients with [Tc
99m] DTPA clearance p100mlmin
 1 had CrCl
estimated that were less predictive than those 4100mlmin
 1.
Rounding up of Scr to 0.06mmoll
 1 improved the predictive
ability of the C&G method for the patients with [Tc
99m] DTPA
clearance p100mlmin
 1, but worsened the effect in those with
4100mlmin
 1.
Four patients (15.4%) were underweight (BMI o18.5kgm
 2),
15 (57.7%) patients were normal weight (BMI 18.5–25kgm
 2) and
seven (26.9%) patients were overweight (BMI o25kgm
 2). The
mean C&G and [Tc
99m] DTPA clearance in BMI categories are
detailed in Table 3.
The r
2 (least-squares line) for the [Tc
99m] DTPA clearance
measurement ranged from 0.9791 –to 0.9999 (mean: 0.9956, s.d.:
0.0061).
DISCUSSION
A small number of patients present with Scr levels o0.06mmoll
 1,
approximately one in 16 patients in this study population. This
study evaluated the common practice of arbitrarily rounding Scr in
these patients to 0.06mmoll
 1. There is no published evidence of
Table 1 Demographic characteristics of patients (n¼26) with Scr values o0.06mmoll
 1
All (n¼26) mean (range) Females (n¼15) mean (range) Males (n¼11) mean (range)
Height (cm) 166 (152–187) 161 (152–170.5) 173 (153–187)
Weight (kg) 62 (32–100) 64.0 (44–100) 60 (32–81)
Age (years) 57 (21–84) 58 (40–76) 57 (21–84)
BSA (m
2) 1.69 (1.17–2.14) 1.68 (1.36–2.14) 1.70 (1.17–1.97)
BMI (kgm
 2) 22.5 (13.7–36.8) 24.6 (17.3–36.8) 20.0 (13.7–27.1)
Scr¼serum creatinine; BSA¼body surface area; BMI¼body mass index.
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specified requirements in assessment of renal function in clinical
trials. The results of this study indicate that this practice does not
result in a reduction in the precision of the C&G formula to
estimate CrCl for patients with GFR p100mlmin
 1, it actually
improves the estimate nearer to the true GFR. Conversely, for
those patients with a GFR 4100mlmin
 1 rounding Scr up to
0.06mmoll
 1 reduced the precision of the estimate. Consequently,
for patients with an Scr less than 0.06mmoll
 1 round upwards
should only be applied to those whose estimated CrCl is less than
p100mlmin
 1. When this rule is applied, the difference between
actual GFR and estimated GFR for GFR p100mlmin
 1 was 7.9%.
There are a number of reasons for very low levels of Scr,
primarily relating to either low level of production or a high
clearance. The rounding up practice is based on the assumption of
the former rather than the latter. The rate of creatinine production
is related to age, sex and body weight, and these are used to scale
relationships between CrCl and Scr (Bjornsson et al, 1983). Serum
creatinine increases with age, more so in women and is at all ages
higher in men (Kesteloot and Joossens, 1996). In patients suffering
from concurrent hepatic diseases, the estimation of CrCl tends to
result in substantial overprediction of observed CrCl. A dimin-
ished rate of creatinine production in patients with hepatic disease
is likely the explanation for this anomaly (Cocchetto et al, 1983).
There are a number of equations and nomograms to estimate
CrCl from Scr concentration (Jelliffe, 1973; Cockcroft and Gault,
1976; Bjornsson et al, 1983; Martin et al, 1998; Wright et al, 2001).
In this study, the C&G formula was applied as this is the most
common formula in routine practice. A number of groups have
assessed the accuracy of the C&G approximation in a variety of
clinical settings. These assessments have usually been compared to
CrCl, determined by the 24-h urine collection (Chow and
Schweizer, 1985; Pesola et al, 1993; Cochran and St John, 1993).
There have also been a number of comparisons of the C&G
approximation with [Tc
99m] DTPA, Cr
51 EDTA and other direct
measures of GFR (Davila and Gardner, 1987; Robinson et al, 1990;
Kesteloot and Joossens, 1996; Millward et al, 1996; Poole et al,
2002). These assessments have almost uniformly concluded that
the C&G approximation underestimates GFR for normal and
moderately reduced levels of renal function.
Our results show that when low levels of Scr are rounded to
0.06mmoll
 1, it actually improves the predictive ability of the
formula for patients with GFR p100mlmin
 1. These results are
Table 2 Calculated CrCl values using actual and rounded Scr values compared to [Tc
99m] DTPA clearance in patients with Scr o0.06mmoll
 1
Mean7s.d. (mlmin
 1) Range (mlmin
 1) MPE (%) P-value
[Tc
99m] DTPA All 111746 45–256
p100mlmin
 1 77714 45–96
4100mlmin
 1 140745 103–256
C&G All 117738 55–207 12.9 0.352
p100mlmin
 1 98728 55–152 29.2 0.024
4100mlmin
 1 135738 86–207  0.1 0.631
C&G (with rounded Scr) All 97730 46–172  7.0 0.029
p100mlmin
 1 82723 46–127 7.9 0.543
4100mlmin
 1 110729 72–172  18.9 0.003
CrCl¼creatinine clearance; Scr¼serum creatinine; [Tc
99m] DTPA¼technetium-99m diethyl triamine penta-acetic acid; C&G¼Cockcroft and Gault; MPE¼mean percentage
error.
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Figure 2 [Tc
99m] DTPA clearance and CrCI estimated by the C&G
method using rounded Scr values.
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Figure 1 [Tc
99m] DTPA clearance and CrCl estimated by the C&G
method using actual Scr values.
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Figure 3 Percentage difference between [Tc
99m] DTPA clearance and
CrCI estimated by the C&G method using actual Scr values.
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with varying renal function who were treated with gentamicin
daily (Kirkpatrick et al, 1999). The clearance of gentamicin was
more accurately predicted when low levels of Scr were also
capped at 0.06mmoll
 1. In another, albeit much smaller study
of critically ill patients, the incorporation of higher corrected
Scr value led to a better prediction of CrCl in cachectic patients
(Robert et al, 1993). This study differed in some ways to ours in
that the criterion standard was inulin clearance. However, other
authors have concluded that rounding of lower Scr concentra-
tions to a higher value before applying in C&G equation results
in poorer correlation with direct measures (Bertino, 1993;
Smythe et al, 1994). A potential reason for the latter conclusion
may be that these papers utilised 24-h urine collection
measurements and rounding to 0.085 and 0.088mmoll
 1,
respectively.
There were only four patients in this study who were
classified as underweight and hence could be expected to be
low producers of muscle creatinine. All these patients had a
normal GFR. In these patients, rounding of Scr resulted in
further reduction in the precision of their GFR estimates. It is
not possible to draw a direct conclusion due to the small
number; however, concerns that overdosing of these individuals
could occur with this method and are not warranted. It is more
likely that lower doses of renally excreted drugs, such as
carboplatin, would be given in these cases as renal function was
underestimated. In the overweight patients, rounding resulted
in improved mean values of CrCl compared with uncorrected
low Scr, suggesting that in such patients low Scr is related to its
enhanced clearance as their mean [Tc
99m] DTPA clearance is
above the normal value of 120mlmin
 1.
There are a number of points that need to be acknowledged
when considering these results. The use of the Jaffe’s method of Scr
measurement has been shown to influence the accuracy of the
estimate; however, the methodology used in the laboratory for this
study has been validated against enzymatic methods and showed
less than 1.2% variability, indicating minimal influence on the
results (Dooley et al, 2002). There was a fairly small number of
subjects included, however, as stated earlier, patients meeting
the criteria for assessment represent a small subset of the
patient population. This study applied direct measurement of
GFR, namely [Tc
99m] DTPA clearance, and the conclusions are
not influenced by limitation of comparison to CrCl estimations
from 24-h urine collections. The C&G formula was utilised
and even though there are other bedside formulae available, all
have similar significant limitations (Poole et al, 2002)]. It must
be noted that when any of these bedside estimates are to be used
for dosage adjustment of renally eliminated drugs, then the
clinician must have an appreciation of the inherent limitations.
When an accurate estimate of GFR is required, then clearance
should be measured using a method such as [Tc
99m] DTPA or Cr
51
EDTA.
This study compared measured GFR ([Tc
99m] DTPA) with
estimated CrCl in patients with Scr levels o0.06mmoll
 1. This
work indicates that when bedside estimates of renal function are
calculated using the C&G formula, then actual Scr should be used
first to estimate CrCl. If the resultant CrCl is p100mlmin
 1, then
the Scr should be rounded up to 0.06mmoll
 1 and CrCl
recalculated. Further assessment of this approach is warranted in
a larger cohort of patients.
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